Business
Notice of Interim Results
Notice of Interim Results.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 2572J Faron Pharmaceuticals Oy 16 August 2019 \n\nFaron Pharmaceuticals Ltd\n(\"Faron\" or the \"Company\")\n \nNotice of Interim Results\n \nTURKU - FINLAND, 16 August 2019 - Faron Pharmaceuticals Ltd (\"Faron\") (LON: FARN), the clinical stage biopharmaceutical company, will announce its unaudited interim results for the six months ended 30 June 2019 on Monday 23 September 2019.\n \nDr Markku Jalkanen, Chief Executive Officer, Toni Hänninen, Chief Financial Officer and Yrjö Wichmann, Vice President, Financing and Investor Relations will host a presentation and conference call for analysts at 9.30am BST on the day of the results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF. Please contact Consilium Strategic Communications for further details.\n \nENDS\n \n \nFor more information please contact:\n \nFaron Pharmaceuticals Ltd\nDr Markku Jalkanen, Chief Executive Officer\[email protected] \n \nConsilium Strategic Communications\nMary-Jane Elliott, David Daley, Lindsey Neville\nPhone: +44 (0)20 3709 5700\nE-mail: [email protected]\n \nWestwicke Partners, IR (US)\nChris Brinzey\nPhone: 01 339 970 2843\nE-Mail: [email protected]\n \nPanmure Gordon (UK) Limited, Nomad and Broker\nEmma Earl, Freddy Crossley\nPhone: +44 207 886 2500\n \nAbout Faron Pharmaceuticals Ltd\n\nFaron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syn...